Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis

Advanced marginal zone lymphoma (MZL) is an incurable B-cell malignancy dependent on B-cell receptor signaling. The phase 2 PCYC-1121 study demonstrated the safety and efficacy of single-agent ibrutinib 560 mg/d in 63 patients with relapsed/refractory MZL treated with prior rituximab (RTX) or rituxi...

詳細記述

保存先:
書誌詳細
出版年:Blood Adv
主要な著者: Noy, Ariela, de Vos, Sven, Coleman, Morton, Martin, Peter, Flowers, Christopher R., Thieblemont, Catherine, Morschhauser, Franck, Collins, Graham P., Ma, Shuo, Peles, Shachar, Smith, Stephen D., Barrientos, Jacqueline C., Chong, Elizabeth, Wu, Shiquan, Cheung, Leo W.-K., Kwei, Kevin, Hauns, Bernhard, Arango-Hisijara, Israel, Chen, Robert
フォーマット: Artigo
言語:Inglês
出版事項: American Society of Hematology 2020
主題:
Clinical Trials and Observations
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7686907/
https://ncbi.nlm.nih.gov/pubmed/33227125
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020003121
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料